Purple biotech to present new clinical data from nt219 at the 2021 asco annual meeting

Initial data from ongoing phase 1/2 clinical trial of nt219 in adults with advanced solid tumors and head and neck cancer to be highlighted
PPBT Ratings Summary
PPBT Quant Ranking